WebMD Health News
Nov. 1, 2013 -- The cholesterol-lowering drug Crestor (rosuvastatin) was the nation's most prescribed drug in the past 12 months, according to a new report from research firm IMS Health. New "...
(mipomersen sodium) Injection
RISK OF HEPATOTOXICITY
KYNAMRO can cause elevations in transaminases. In the KYNAM RO clinical trial in patients with HoFH, 4 (12%) of the 34 patients treated with KYNAMRO compared with 0% of the 17 patients treated with placebo had at least one elevation in alanine aminotrans ferase (ALT) ≥ 3x upper limit of normal (ULN). There were no concomitant clinically meaningful elevations of total bilirubin, international normalized ratio (INR) or partial thromboplastin time (PTT) [see WARNINGS AND PRECAUTIONS].
KYNAMRO also increase she paticfat, with or without concomitant increases in transaminases. In the trials in patients with heterozygous familial hypercholesterolemia (He FH) and hyperlipidemia, the median absolute increase in hepatic fat was 10% after 26 weeks of treatment, from 0% at base line, measured by magnetic resonance imaging (MRI). Hepatic steatosis is a risk factor for advanced liver disease; including steatohepatitis and cirrhosis [see WARNINGS AND PRECAUTIONS].
Measure ALT, AST, alkaline phosphatase, and total bilirubin before initiating treatment and then ALT, AST regularly as recommended. During treatment, withhold the dose of KYNAMRO if the ALT or AST are ≥ 3 x ULN. Discontinue KYNAMRO for clinically significant liver toxicity [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS].
Because of the risk of hepatotoxicity, KYNAMRO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the KYNAMRO REMS [see WARNINGS AND PRECAUTIONS]. Prescribe KYNAM RO only to patients with a clinical or laboratory diagnosis consistent with HoFH. The safety and effectiveness of KYNAM RO have not been established in patients with hyperchole sterolemia who do not have HoFH (1).
KYNAMRO (mipomersen sodium) Injection is a sterile, preservative-free, clear, colorless to slightly yellow, aqueous solution for subcutaneous injection. KYNAMRO is supplied in single-use, 1 mL, clear glass pre-filled syringes filled to deliver 1 mL of solution containing 200 mg of mipomersen sodium (200 mg per 1 mL). KYNAMRO is formulated in water for injection and may include hydrochloric acid and/or sodium hydroxide for pH adjustment to 7.5 – 8.5.
Mipomersen sodium is an oligonucleotide inhibit or of apoB-100 synthesis. ApoB is the principal apolipoprote in of LDL and its metabolic precursor, very low density lipoprotein (VLDL). Mipomersen inhibits synthesis of apoB by sequence-specific binding to its messenger ribonucleic acid (mRNA) resulting in degradation of the mRNA through enzyme-mediated pathways or disruption of mRNA function through binding alone.
Mipomersen sodium is a synthetic phosphorothioate oligonucleotide sodium salt, 20 nucleotides in length, with the following sequence:
where the underlined residues are 2'-O-(2-methoxyethy l) nucleosides; all other residues are 2'-deoxynucleosides. Substitution at the 5-position of the cytosine (C) and uracil (U) bases with a methyl group is indicated byMe.
Mipomersen sodium is represented by the following structural formula:
The molecular formula of mipomersen sodium is C230H305N67O122P19S19Na19 and the molecular weight is 7594.9 g/mol.
What are the possible side effects of mipomersen (Kynamro)?
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Stop using mipomersen and call your doctor at once if you have:
- fever, chills, body aches, flu symptoms, joint pain;
- pain, swelling, redness, itching, bruising, or tenderness where an injection was given; or
- nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Common side effects may...
Last reviewed on RxList: 6/7/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Kynamro Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Tips to keep it under control.